Necrostatin-1S mitigates type-2 diabetes-associated cognitive decrement and lipotoxicity-induced neuro-microglia changes through p-RIPK-RIPK3-p-MLKL axis

Preeti, Kumari; Fernandes, Valencia; Sood, Anika; Khan, Islauddin; Khatri, Dharmendra Kumar; Singh, Shashi Bala

doi:10.1007/s11011-023-01185-8

Search citation statements

Order By: Relevance

Paper Sections

Select...

Other Rip Inhibitors In Neurological Disorders1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article5

Preprint1

Relationship

Self Cite0

Independent6

Authors

Journals

Cited by 7 publications

(1 citation statement)

References 91 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Besides the Necrostatin-1, Necrostatin-1 s is another important RIP1 inhibitor. Preeti et al (2023) want to evaluate the neuroprotective effect of Necrostatin-1 s in the type-2 diabetes mellitus model. They found that Necrostatin-1 s mitigates cognitive decrement.…”

Section: Other Rip Inhibitors In Neurological Disordersmentioning

confidence: 99%

Necrostatin-1: a promising compound for neurological disorders

Chen,

Wang,

Lei

et al. 2024

Front. Cell. Neurosci.

View full text Add to dashboard Cite

Necrostatin-1, a small molecular alkaloid, was identified as an inhibitor of necroptosis in 2005. Investigating the fundamental mechanism of Necrostatin-1 and its role in various diseases is of great significance for scientific and clinical research. Accumulating evidence suggests that Necrostatin-1 plays a crucial role in numerous neurological disorders. This review aims to provide a comprehensive overview of the potential functions of Necrostatin-1 in various neurological disorders, offering valuable insights for future research.

show abstract

Section: Other Rip Inhibitors In Neurological Disordersmentioning

confidence: 99%